| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Over the last 12 months, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of ABVC BioPharma, Inc. stock.
On average, over the past 5 years, insiders at ABVC BioPharma, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $1,500 was made by Nirta Joseph (director) on 2010‑05‑11.
| 2010-05-11 | Nirta Joseph | director | 10,000 0.0305% | $0.15 | $1,500 | |||
| 2010-03-22 | Nirta Joseph | director | 2,000 0.0061% | $0.26 | $520 | |||
| 2009-10-01 | Stromback Richard Dean | 10 percent owner | 240 – | $0.42 | $101 | |||
| 2009-04-14 | Smith J.B. | 21 <0.0001% | $0.75 | $16 | ||||
| 2009-01-23 | Sale | Stromback Richard Dean | 4M 13.8448% | $1.00 | $4M | |||
| 2009-01-23 | Smith J.B. | 4M 13.8448% | $1.00 | $4M | ||||
| 2008-08-18 | Sale | Stromback Richard Dean | CEO | 1.5M 0.3123% | $1.00 | $1.5M | ||
| 2007-07-30 | Ramsey Sally Judith | VP New Product Development | 3M – | $0 | $0 |
| Increased Positions | 5 | +35.71% | 80,241 | +19.6% |
| Decreased Positions | 5 | -35.71% | 201,971 | -49.34% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 3 | Sold Out | 200,646 | Sold Out |
| Total Postitions | 14 | 0% | 287,597 | -29.74% |
| Geode Capital Management, Llc | $83.00 | 0.47% | 79,285 | +7,678 | +10.72% | 2024-12-31 |
| Vanguard Group Inc | $49.00 | 0.28% | 46,947 | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $43.00 | 0.24% | 40,743 | +40,743 | New | 2024-12-31 |
| Xtx Topco Ltd | $36.00 | 0.2% | 34,405 | +11,000 | +47% | 2024-12-31 |
| Northern Trust Corp | $20.00 | 0.11% | 19,135 | 0 | 0% | 2024-12-31 |
| Virtu Financial Llc | $17.00 | 0.09% | 15,935 | +15,935 | New | 2024-12-31 |
| State Street Corp | $14.00 | 0.08% | 12,900 | 0 | 0% | 2024-12-31 |
| Two Sigma Securities, Llc | $13.00 | 0.07% | 12,593 | +196 | +1.58% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $3.00 | 0.02% | 2,563 | -60 | -2.29% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 460 | -202 | -30.51% | 2025-03-31 |